We are a team of clinician-scientists (nephrologists and transplant physicians), biotechnologists, biochemists and molecular biologists. Our primary interest is to inhibit clinically relelevant necrotic type cell death pathways and the inflammatory response (immunogenicity) associated with necrosis (necroinflammation). Pathways of regulated necrosis are necroptosis, ferroptosis and pyroptosis.